Bank of New York Mellon’s Adaptive Biotechnologies ADPT Stock Holding History

Bank of New York Mellon’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.21M	Buy	429,229 +27,328	+7%	+$419K	﹤0.01%	2077
2026 Q1	$5.58M	Sell	401,901 -11,352	-3%	-$181K	﹤0.01%	2249
2025 Q4	$6.71M	Sell	413,253 -11,256	-3%	-$184K	﹤0.01%	2155
2025 Q3	$6.35M	Buy	424,509 +13,957	+3%	+$170K	﹤0.01%	2188
2025 Q2	$4.78M	Buy	410,552 +52,484	+15%	+$477K	﹤0.01%	2288
2025 Q1	$2.66M	Sell	358,068 -5,838	-2%	-$44.9K	﹤0.01%	2551
2024 Q4	$2.18M	Sell	363,906 -5,780	-2%	-$31.9K	﹤0.01%	2725
2024 Q3	$1.89M	Sell	369,686 -90,446	-20%	-$394K	﹤0.01%	2774
2024 Q2	$1.67M	Buy	460,132 +64,788	+16%	+$206K	﹤0.01%	2898
2024 Q1	$1.27M	Sell	395,344 -19,638	-5%	-$76K	﹤0.01%	3024
2023 Q4	$2.03M	Buy	414,982 +39,074	+10%	+$178K	﹤0.01%	2828
2023 Q3	$2.05M	Buy	375,908 +2,325	+0.6%	+$15.4K	﹤0.01%	2795
2023 Q2	$2.51M	Sell	373,583 -7,624	-2%	-$56.7K	﹤0.01%	2712
2023 Q1	$3.37M	Sell	381,207 -10,356	-3%	-$91.3K	﹤0.01%	2506
2022 Q4	$2.99M	Sell	391,563 -6,768	-2%	-$52.7K	﹤0.01%	2623
2022 Q3	$2.84M	Buy	398,331 +18,897	+5%	+$178K	﹤0.01%	2614
2022 Q2	$3.07M	Sell	379,434 -526,335	-58%	-$4.63M	﹤0.01%	2593
2022 Q1	$12.6M	Sell	905,769 -23,418	-3%	-$368K	﹤0.01%	1953
2021 Q4	$26.1M	Sell	929,187 -2,185	-0.2%	-$67K	﹤0.01%	1562
2021 Q3	$31.7M	Buy	931,372 +25,869	+3%	+$936K	0.01%	1448
2021 Q2	$37M	Buy	905,503 +33,928	+4%	+$1.32M	0.01%	1363
2021 Q1	$35.1M	Buy	871,575 +4,042	+0.5%	+$219K	0.01%	1361
2020 Q4	$51.3M	Buy	867,533 +83,916	+11%	+$4.33M	0.01%	1035
2020 Q3	$38.1M	Buy	783,617 +77,282	+11%	+$3.25M	0.01%	1067
2020 Q2	$34.2M	Buy	706,335 +562,170	+390%	+$20.5M	0.01%	1118
2020 Q1	$4M	Buy	144,165 +101,849	+241%	+$2.84M	﹤0.01%	2184
2019 Q4	$1.27M	Buy	42,316 +11,606	+38%	+$333K	﹤0.01%	3109
2019 Q3	$949K	Buy	+30,710	New	+$1.25M	﹤0.01%	3207

Other funds holding ADPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

GIP

Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Bank of New York Mellon's ADPT Position: Q2 2026 in Review

Bank of New York Mellon increased its Adaptive Biotechnologies (ADPT) stake by 6.8% in Q2 2026, buying an estimated $419K and bringing the position to 429,229 shares worth $9.21M. The position accounts for ﹤0.01% of the portfolio, ranked #2077.

Bank of New York Mellon first reported a position in ADPT in Q3 2019 and has held it in 28 quarters since. The position peaked at $51.3M in Q4 2020. 156 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

Bank of New York Mellon held 429,229 shares of Adaptive Biotechnologies worth $9.21M as of Q2 2026.
Bank of New York Mellon bought 27,328 Adaptive Biotechnologies shares in Q2 2026, an estimated $419K.
Adaptive Biotechnologies made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2077 holding.
Bank of New York Mellon first reported a position in Adaptive Biotechnologies in Q3 2019 and has held it in 28 quarters since.
Bank of New York Mellon's Adaptive Biotechnologies position peaked at $51.3M in Q4 2020.
156 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.